Core Viewpoint - The company, Innovation Qizhi (02121), has repurchased a total of 570,100 shares for a total consideration of HKD 4.3055 million in October 2025, reflecting confidence in its business outlook and future prospects [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased 570,100 shares in the open market at a total cost of HKD 4.3055 million [1] - **Management's Perspective** - The board believes that the share buyback demonstrates confidence in the company's business outlook and will ultimately benefit the company and create value for shareholders [1] - **Financial Position** - The board asserts that the company's existing financial resources are sufficient to support the share buyback while maintaining a robust financial condition [1]

Core Viewpoint - The company, Innovent Biologics (02121), has repurchased a total of 570,100 shares in the open market for a total consideration of HKD 4.3055 million, reflecting confidence in its business outlook and future prospects [1] Summary by Sections - **Share Buyback Details** - The company repurchased 570,100 shares in October 2025 [1] - The total cost of the share buyback was HKD 4.3055 million [1] - **Board's Perspective** - The board believes that the share buyback demonstrates confidence in the company's business outlook and future prospects [1] - The board anticipates that the buyback will ultimately benefit the company and create value for shareholders [1] - The company has sufficient financial resources to support the buyback while maintaining a robust financial position [1]

Group 1 - The company, Innovation Works (02121.HK), announced the repurchase of shares under its buyback authorization [1] - A total of 570,100 shares were repurchased in the open market [1] - The total cost of the share repurchase amounted to HKD 4.3055 million [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 創新奇智科技集團股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02121 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 563,544,438 | RMB | | 1 RMB | | 563,544,438 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 563,544,438 | RMB | | 1 RMB | | 563,544,438 | 本月底法定/註 ...

AINNOVATION TECHNOLOGY GROUP CO., LTD* 創新奇智科技集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2121） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 股東及潛在投資者務須注意，股份購回將視乎市況及由董事會全權酌情決定。概不能保證任何股份 購回之時間、數量或價格。因此，股東及潛在投資者於買賣股份時務須審慎行事。 承董事會命 AINNOVATION TECHNOLOGY GROUP CO., LTD* 創新奇智科技集團股份有限公司 執行董事兼首席執行官 自願性公告 股份購回的最新情況 此乃創新奇智科技集團股份有限公司（「本公司」）之自願性公告，旨在向本公司股東（「股東」）及潛在 投資者提供有關本公司最新發展之資料。 茲提述本公司日期為2025年5月16日之自願性公告（「該公告」），內容有關（其中包括）本公司董事 會（「董事會」）擬根據股東於2025年5月16日舉行之年度股東會授出之購 ...

Core Insights - The prices of old national standard electric bicycles are rising as the transition period to the new national standard approaches, with some models increasing by 100 to 300 yuan [1][2][4] - There is a significant scarcity of old national standard models in the market, as manufacturers have ceased production of these models since September 1, 2023, leading to a rush among consumers to purchase remaining stock before the new regulations take effect [2][3][5] - New national standard models are largely absent from the market, with manufacturers possibly controlling the release schedule to avoid impacting sales of existing old standard inventory [4][5] Industry Dynamics - The new national standard, effective December 1, 2025, imposes stricter safety and performance requirements, which presents both challenges and opportunities for manufacturers [6][7] - Companies are required to redesign products, upgrade production lines, and adapt supply chains to meet the new regulations, which may strain their operational capabilities [6] - Some brands, such as Ninebot, Green Source, and Tailin, have already developed models that comply with the new standards, with plans to launch these products starting in December 2023 [7]

Summary of Key Points Core Viewpoint - On October 17, 42 Hong Kong-listed companies conducted share buybacks, totaling 46.36 million shares and an aggregate amount of HKD 621 million [1][2]. Company-Specific Summaries - **Xiaomi Group-W**: - Repurchased 10.70 million shares for HKD 494 million, with a highest price of HKD 46.760 and a lowest price of HKD 45.900. The total buyback amount for the year reached HKD 1.537 billion [1][2]. - **Sihuan Pharmaceutical**: - Repurchased 15 million shares for HKD 21.76 million, with a highest price of HKD 1.470 and a lowest price of HKD 1.430. The total buyback amount for the year reached HKD 143.32 million [1][2]. - **Mengniu Dairy**: - Repurchased 1.20 million shares for HKD 16.97 million, with a highest price of HKD 14.250 and a lowest price of HKD 14.070. The total buyback amount for the year reached HKD 433.54 million [1][2]. - **AAC Technologies**: - Repurchased 300,000 shares for HKD 11.60 million, with a highest price of HKD 38.800 and a lowest price of HKD 38.480. The total buyback amount for the year reached HKD 84.64 million [1][2]. - **Vitasoy International**: - Repurchased 1.02 million shares for HKD 8.20 million, with a highest price of HKD 8.040 and a lowest price of HKD 8.020. The total buyback amount for the year reached HKD 27.54 million [1][2]. Overall Market Activity - The highest buyback amount on October 17 was from Xiaomi Group-W at HKD 494 million, followed by Sihuan Pharmaceutical at HKD 21.76 million. Other notable companies included Mengniu Dairy and AAC Technologies [1][2]. - In terms of share quantity, Sihuan Pharmaceutical led with 15 million shares repurchased, followed by Xiaomi Group-W with 10.70 million shares and Anton Oilfield Services with 4.49 million shares [1][2].

Core Viewpoint - Multiple companies in China conducted share buybacks on October 17, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1][2] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 10.70 million shares for a total of 494 million yuan, with a year-to-date total of 27.30 million shares, representing 0.110% of its total share capital [2] - Four Seasons Pharmaceutical (00460) repurchased 15 million shares for 21.76 million yuan, with a year-to-date total of 59.60 million shares, representing 0.647% of its total share capital [2] - Mengniu Dairy (02319) repurchased 1.20 million shares for 16.97 million yuan, with a year-to-date total of 18.52 million shares, representing 0.473% of its total share capital [2] Group 2: Other Notable Buybacks - VITASOY International (00345) repurchased 1.02 million shares for 8.20 million yuan, with a year-to-date total of 566.60 million shares, representing 0.540% of its total share capital [2] - Zhongtong Express-W (02057) repurchased 445,000 shares for 8.41 million yuan, with a year-to-date total of 5.07 million shares, representing 0.630% of its total share capital [2] - Huazhong Media (00685) repurchased 500,000 shares for 50,000 yuan, with a year-to-date total of 225.60 million shares, representing 0.139% of its total share capital [2]

Core Viewpoint - The company, Innovent Biologics (02121), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will spend HKD 1.482 million to repurchase 220,100 shares [1] - The buyback price per share ranges from HKD 6.67 to HKD 6.80 [1]

Core Viewpoint - Innovation Works (02121.HK) announced a share buyback on October 17, 2025, spending HKD 1.482 million to repurchase 220,100 shares at a price range of HKD 6.67 to 6.80 per share [1] Summary by Category - **Company Actions** - The company executed a buyback of 220,100 shares at a total cost of HKD 1.482 million [1] - The buyback price per share ranged from HKD 6.67 to HKD 6.80 [1]